CHAMPAIGN, Ill. — A new drug that prompts cancer cells to self-destruct while sparing healthy cells is now entering phase I clinical trials in humans. The drug, called PAC-1, first showed promise in the treatment of pet dogs with spontaneously occurring cancers, and is still in clinical trials in dogs with osteosarcoma.
Announcements, events, and opportunities for members of the Cancer Community at Illinois.
Nicole Rogus-Pulia, from left, of University of Wisconsin-Madison and Karin Rosenblatt of the University of Illinois at Urbana-Champaign will each be giving talks focusing on cancer topics next week. Find out more in this week's digest.
A new technique being developed by Kris Kilian could revolutionize medicine by enabling a patient’s own cells to be reverted back and modified to correct mutations and regenerate injured tissues. Kilian recently received a National Science Foundation CAREER Award for this work and for his initiative in educating students about stem cell engineering.
Physics professor Taekjip Ha led research to develop a new tool, called a "tension gauge tether," that allows scientists to measure cell mechanics at the single-molecule level which is crucial to understanding how they activate a wide range of cellular functions, such as cell reproduction, differentiation, and adhesion — basic physiological processes that underlie embryo development, tumor metastasis, wound healing, and other aspects of human health and disease.